Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia

Hydroxyurea therapy has proven laboratory and clinical efficacies for children with sickle cell anemia (SCA). When administered at maximum tolerated dose (MTD), hydroxyurea increases fetal hemoglobin (HbF) to levels ranging from 10% to 40%. However, interpatient variability of percentage of HbF (%Hb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ware, Russell E., Despotovic, Jenny M., Mortier, Nicole A., Flanagan, Jonathan M., He, Jin, Smeltzer, Matthew P., Kimble, Amy C., Aygun, Banu, Wu, Song, Howard, Thad, Sparreboom, Alex
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208303/
https://ncbi.nlm.nih.gov/pubmed/21876119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-364190
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados